Improved patient outcome with smoking cessation: When is it too late?

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 259-267

  Wu, Jane ^a   Sin, Don D ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

COPD; Lung cancer; Smoking cessation; Tobacco treatment

Indexed keywords

AMFEBUTAMONE; CORTICOSTEROID; NICOTINE; PLACEBO; PREDNISOLONE; VARENICLINE;

ABDOMINAL CRAMP; ABNORMAL DREAMING; ASTHMA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH PROMOTION; HOSPITALIZATION; HUMAN; INSOMNIA; INTERVENTION STUDY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NAUSEA; NICOTINE REPLACEMENT THERAPY; NIGHTMARE; OUTCOME ASSESSMENT; POLICY; PREDICTION; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SLEEP DISORDER; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TREATMENT DURATION; WEIGHT GAIN; HEART INFARCTION; LUNG TUMOR; MORTALITY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; TIME; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

HEALTH PROMOTION; HUMANS; LUNG NEOPLASMS; MYOCARDIAL INFARCTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84862833519     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S10771     Document Type: Review

References (69)

1. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. Sep 13 2003;362(9387):847-852.
2. World Health Organization. World Health Report 2002. Geneva, Switzerland: WHO; 2002.
3. World Health Organization. WHO Report on the Global Tobacco Epidemic 2009: Implementing Smoke-free Environments. Geneva, Switzerland: WHO; 2009.
4. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Betheseda, MD: US Public Health Service, Office on Smoking and Health; 1990.
5. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233-239.
6. Connett JE, Murray RP, Buist AS, et al. Changes in smoking status affect women more than men: results of the Lung Health Study. Am J Epidemiol. 2003;157(11):973-979.
7. Anthonisen NR, Connett JE, Kiley J P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodila-tor on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272(19):1497-1505.
8. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009;180(1):3-10.
9. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645-1648.
10. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003;97(2):115-122.
11. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388-393.
12. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741-750.
13. Wilson D, Adams R, Appleton S, Ruffn R. Diffculties identifying and targeting COPD and population-attributable risk of smoking for COPD: a population study. Chest. 2005;128(4):2035-2042.
14. Coultas DB, Howard CA, Peake GT, Skipper BJ, Samet JM. Salivary cotinine levels and involuntary tobacco smoke exposure in children and adults in New Mexico. Am Rev Respir Dis. 1987;136(2):305-309.
15. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675-679.
16. Murray R P, Anthonisen NR, Connett JE, et al. Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. Lung Health Study Research Group. J Clin Epidemiol. 1998;51(12):1317-1326.
17. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166(3):333-339.
18. Multiple Risk Factor Interventional Trial Study Group. Mortality after 16 years for participants randomized to the Multiple Risk Factor Intervention Trial. Circulation. 1996;94(5):946-951.
19. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005;60(7):570-575.
20. Eberly LE, Ockene J, Sherwin R, Yang L, Kuller L. Pulmonary function as a predictor of lung cancer mortality in continuing cigarette smokers and in quitters. Int J Epidemiol. 2003;32(4):592-599.
21. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438): 937-952.
22. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368(9536):647-658.
23. Jang AS, Park S W, Kim DJ, et al. Effects of smoking cessation on airflow obstruction and quality of life in asthmatic smokers. Allergy Asthma Immunol Res. 2010;2(4):254-259.
24. Tonnesen P, Pisinger C, Hvidberg S, et al. Effects of smoking cessation and reduction in asthmatics. Nicotine Tob Res. 2005;7(1):139-148.
25. Chaudhuri R, Livingston E, McMahon AD, et al. Effects of smoking cessation on lung function and airway infammation in smokers with asthma. Am J Respir Crit Care Med. 2006;174(2):127-133.
26. Krzyzanowski M, Robbins DR, Lebowitz MD. Smoking cessation and changes in respiratory symptoms in two populations followed for 13 years. Int J Epidemiol. 1993;22(4):666-673.
27. Lemiere C, Boulet LP. Cigarette smoking and asthma: a dangerous mix. Can Respir J. 2005;12(2):79-80.
28. Piipari R, Jaakkola JJ, Jaakkola N, Jaakkola MS. Smoking and asthma in adults. Eur Respir J. 2004;24(5):734-739.
29. Stallberg B, Lisspers K, Hasselgren M, Johansson G, Svardsudd K. Factors related to the level of severity of asthma in primary care. Respir Med. 2007;101(10):2076-2083.
30. Siroux V, Pin I, Oryszczyn M P, Le Moual N, Kauffmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. Eur Respir J. 2000;15(3):470-477.
31. Strine T W, Balluz LS, Ford ES. The associations between smoking, physical inactivity, obesity, and asthma severity in the general US population. J Asthma. 2007;44(8):651-658.
32. O'Byrne PM, Lamm CJ, Busse WW, Tan WC, Pedersen S. The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma. Chest. 2009;136(6):1514-1520.
33. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998;339(17):1194-1200.
34. Fanta CH. Asthma. N Engl J Med. 2009;360(10):1002-1014.
35. Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175(8):783-790.
36. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 2001;15(6):1110-1112.
37. Chalmers G W, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway infammation in patients with mild asthma. Chest. 2001;120(6):1917-1922.
38. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123 (1 Suppl):21S-49S.
39. Parsons A, Daley A, Begh R, Aveyard P. Infuence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010;340:b5569.
40. Shah AM, Pfeffer MA, Hartley LH, et al. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol. 2010;106(7):911-916.
41. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myo-cardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-677.
42. Wise RA, Enright PL, Connett JE, et al. Effect of weight gain on pulmonary function after smoking cessation in the Lung Health Study. Am J Respir Crit Care Med. 1998;157(3 Pt 1):866-872.
43. Cigarette smoking among adults - United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51(29):642-645.
44. Leatherdale ST, Shields M. Smoking cessation: intentions, attempts and techniques. Health Rep. Sep 2009;20(3):31-39.
45. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99(1):29-38.
46. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010;65(8):711-718.
47. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J. 2009;34(3):634-640.
48. Stratelis G, Molstad S, Jakobsson P, Zetterstrom O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care. 2006;24(3):133-139.
49. Bize R, Burnand B, Mueller Y, Rege Walther M, Cornuz J. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev. 2009;(2):CD004705.
50. Kotz D, Wesseling G, Huibers MJ, van Schayck OC. Effcacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J. 2009;33(4):754-762.
51. Parkes G, Greenhalgh T, Griffn M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336(7644):598-600.
52. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest. 2006;130(2):334-342.
53. Tran K, Asakawa K, Cimon K, et al. Pharmacologic-based Strategies for Smoking Cessation: Clinical and Cost-Effectiveness Analyses Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010. (Technology Report; no. 130). [cited 2010-09-21]. Available from: http://www.cadth.ca/index.php/en/hta/reports-publica-tions/search?&type=16. Accessed 11 Feb 2011.
54. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24): 2295-2303.
55. Lewis SF, Piasecki TM, Fiore MC, Anderson JE, Baker TB. Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial. Prev Med. 1998;27(2):296-303.
56. Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation. A randomized trial with telephone counseling. Arch Intern Med. 1993;153(16):1917-1923.
57. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685-691.
58. Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med. 2002;346(7):506-512.
59. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001;357(9268):1571-1575.
60. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Effcacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med. 2005;165(19):2286-2292.
61. Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med. 2006; 119(12):1080-1087.
62. Simon JA, Duncan C, Huggins J, Solkowitz S, Carmody TP. Sustained-release bupropion for hospital-based smoking cessation: a randomized trial. Nicotine Tob Res. 2009;11(6):663-669.
63. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med. 2008;359(19):2018-2024.
64. Tashkin D P, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in mild-to-moderate COPD: A randomized controlled trial. Chest. 2010 Sep 23. [Epub before print].
65. Beasley MB. Smoking-related Small airway disease - a review and update. Adv Anat Pathol. 2010;17(4):270-276.
66. Nakanishi M, Demura Y, Mizuno S, et al. Changes in HRCT fndings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation. Eur Respir J. 2007; 29(3):453-461.
67. Vassallo R, Ryu JH. Tobacco smoke-related diffuse lung diseases. Semin Respir Crit Care Med. 2008;29(6):643-650.
68. Beasley MB. Smoking-related small airway disease - a review and update. Adv Anat Pathol. 2010;17(4):270-276.
69. The Multiple Risk Factor Intervention Trial Research Group. Mortality after 16 years for participants randomized to The Multiple Risk Factor Intervention Trial Research Group. Circulation. 1996;94(5):946-951.